Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine HCl ER PK in ESRD Patients on Hemodialysis
NCT02373215Phase 1Completed
- Sponsor
- Trevi Therapeutics
- Start
- Apr 2013
- Primary completion
- Nov 2013
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label trial of nalbuphine in uremic pruritus (3 cohorts), sponsored by Trevi Therapeutics. Primary endpoints: Steady state Pharmacokinetics and Extent of extraction of nalbuphine. Started Apr 2013; status: completed.
02
Drugs
nalbuphine
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT02373215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02373215.